| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 543 | 2018 |
| Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small cell lung cancer NB Leighl, RD Page, VM Raymond, DB Daniel, SG Divers, KL Reckamp, ... Clinical cancer research 25 (15), 4691-4700, 2019 | 487 | 2019 |
| Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with … RJ Motzer, CH Barrios, TM Kim, S Falcon, T Cosgriff, WG Harker, ... Journal of Clinical Oncology 32 (25), 2765, 2014 | 398 | 2014 |
| Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer NK Ibrahim, B Samuels, R Page, D Doval, KM Patel, SC Rao, MK Nair, ... J Clin Oncol 23 (25), 6019-6026, 2005 | 353 | 2005 |
| Primary hepatic lymphoma: favorable outcome after combination chemotherapy RD Page, JE Romaguera, B Osborne, LJ Medeiros, J Rodriguez, L North, ... Cancer 92 (8), 2023-2029, 2001 | 221 | 2001 |
| Changing physician incentives for affordable, quality cancer care: results of an episode payment model LN Newcomer, B Gould, RD Page, SA Donelan, M Perkins Journal of oncology practice 10 (5), 322-326, 2014 | 155 | 2014 |
| Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer MA Socinski, CJ Langer, I Okamoto, JK Hon, V Hirsh, SR Dakhil, RD Page, ... Annals of Oncology 24 (2), 314-321, 2013 | 136 | 2013 |
| American Society of Clinical Oncology policy statement on clinical pathways in oncology RT Zon, JN Frame, MN Neuss, RD Page, DS Wollins, S Stranne, ... Journal of Oncology Practice 12 (3), 261-266, 2016 | 112 | 2016 |
| Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with … RJ Motzer, CH Barrios, TM Kim, S Falcon, T Cosgriff, WG Harker, ... Journal of Clinical Oncology 31 (15_suppl), 4504-4504, 2013 | 112 | 2013 |
| PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer H Yu, C Batenchuk, A Badzio, TA Boyle, P Czapiewski, DC Chan, X Lu, ... Journal of Thoracic Oncology 12 (1), 110-120, 2017 | 110 | 2017 |
| Telehealth in oncology: ASCO standards and practice recommendations RT Zon, EB Kennedy, K Adelson, S Blau, N Dickson, D Gill, N Laferriere, ... JCO Oncology Practice 17 (9), 546-564, 2021 | 96 | 2021 |
| Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC JJ Knox, CH Barrios, TM Kim, T Cosgriff, V Srimuninnimit, K Pittman, ... Annals of Oncology 28 (6), 1339-1345, 2017 | 85 | 2017 |
| Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer MA Socinski, I Okamoto, JK Hon, V Hirsh, SR Dakhil, RD Page, J Orsini, ... Annals of oncology 24 (9), 2390-2396, 2013 | 83 | 2013 |
| Opioids and cancer pain: patients’ needs and access challenges R Page, E Blanchard Journal of oncology practice 15 (5), 229-231, 2019 | 75 | 2019 |
| Principles of chemotherapy R Page, C Takimoto Cancer Management: A Multidisciplinary Approach Medical, Surgical …, 2004 | 69 | 2004 |
| P3. 02c-026 is nivolumab safe and effective in elderly and PS2 patients with non-small cell lung cancer (NSCLC)? Results of CheckMate 153: Topic: IT D Spigel, L Schwartzberg, D Waterhouse, J Chandler, M Hussein, R Jotte, ... Journal of Thoracic Oncology 12 (1), S1287-S1288, 2017 | 61 | 2017 |
| American Society of Clinical Oncology criteria for high-quality clinical pathways in oncology RT Zon, SB Edge, RD Page, JN Frame, GH Lyman, JL Omel, DS Wollins, ... Journal of oncology practice 13 (3), 207-210, 2017 | 47 | 2017 |
| Pernicious anemia: presentations mimicking acute leukemia C Aitelli, L Wasson, R Page Southern medical journal 97 (3), 295-298, 2004 | 47 | 2004 |
| Occupational and personal consequences of the COVID-19 pandemic on US oncologist burnout and well-being: A study from the ASCO Clinician Well-Being Task Force FJ Hlubocky, AL Back, TD Shanafelt, CM Gallagher, JM Burke, AH Kamal, ... JCO Oncology Practice 17 (7), e427-e438, 2021 | 40 | 2021 |
| Oncology clinical pathways: charting the landscape of pathway providers B Daly, RT Zon, RD Page, SB Edge, GH Lyman, SR Green, DS Wollins, ... J Oncol Pract 14 (3), e194-e200, 2018 | 37 | 2018 |
